Literature DB >> 7853572

Hereditary papillary renal cell carcinoma: clinical studies in 10 families.

B Zbar1, G Glenn, I Lubensky, P Choyke, M M Walther, G Magnusson, U S Bergerheim, S Pettersson, M Amin, K Hurley.   

Abstract

We recently described a 3-generation family with members affected with papillary renal cell carcinoma, an uncommon histological type of renal cell carcinoma. Possibly family 150 is an isolated occurrence, a reflection of some as yet unknown environmental factor. Alternatively, family 150 may represent a distinct class of inherited cancer. To distinguish between these 2 possibilities we sought additional families with papillary renal cell carcinoma and we identified 9 with members affected with papillary renal cell carcinoma. There were 29 affected male and 12 affected female subjects (ratio 2.41:1), including affected members of family 150. Papillary renal cell carcinomas were often detected incidentally in asymptomatic individuals or during screening of asymptomatic members of renal cell carcinoma families. The penetrance, the proportion of obligate gene carriers that showed clinical evidence of the disease, was reduced. The median survival of affected individuals was 52 years. The results support the concept that the predisposition to develop papillary renal cell carcinomas may be inherited and that hereditary papillary renal cell carcinoma constitutes a distinct class of inherited cancer.

Entities:  

Mesh:

Year:  1995        PMID: 7853572

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  35 in total

Review 1.  Familial adult renal neoplasia.

Authors:  M Takahashi; R Kahnoski; D Gross; D Nicol; B T Teh
Journal:  J Med Genet       Date:  2002-01       Impact factor: 6.318

2.  Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.

Authors:  E R Woodward; S C Clifford; D Astuti; N A Affara; E R Maher
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

Review 3.  Hereditary kidney cancer syndromes.

Authors:  Naomi B Haas; Katherine L Nathanson
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

Review 4.  Targeted therapies for non-clear renal cell carcinoma.

Authors:  Eric A Singer; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Target Oncol       Date:  2010-08-03       Impact factor: 4.493

5.  Impact of genetics on the diagnosis and treatment of renal cancer.

Authors:  Eric A Singer; Gennady Bratslavsky; Lindsay Middelton; Ramaprasad Srinivasan; W Marston Linehan
Journal:  Curr Urol Rep       Date:  2011-02       Impact factor: 3.092

Review 6.  The metabolic basis of kidney cancer.

Authors:  W Marston Linehan; Christopher J Ricketts
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

7.  Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.

Authors:  I A Lubensky; L Schmidt; Z Zhuang; G Weirich; S Pack; N Zambrano; M M Walther; P Choyke; W M Linehan; B Zbar
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

8.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.

Authors:  Youfeng Yang; Vladimir A Valera; Hesed M Padilla-Nash; Carole Sourbier; Cathy D Vocke; Manish A Vira; Mones S Abu-Asab; Gennady Bratslavsky; Maria Tsokos; Maria J Merino; Peter A Pinto; Ramaprasad Srinivasan; Thomas Ried; Len Neckers; W Marston Linehan
Journal:  Cancer Genet Cytogenet       Date:  2010-01-01

9.  Nuclear Pedigree Criteria for the Identification of Individuals Suspected to be at Risk of an Inherited Predisposition to Renal Cancer.

Authors:  Aleksandra Tołoczko-Grabarek; Andrzej Sikorski; Marek Brzosko; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2005-08-15       Impact factor: 2.857

Review 10.  Targeting the Met signaling pathway in renal cancer.

Authors:  Alessio Giubellino; W Marston Linehan; Donald P Bottaro
Journal:  Expert Rev Anticancer Ther       Date:  2009-06       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.